Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Amati also took a hit on Synairgen’s Covid drug SNG001, which produced unexpectedly poor Phase 3 trial results, so he must have particularly broad (investment) shoulders at the moment.
The problem is that steroids were never mentioned in the Sprinter Trial protocol
https://clinicaltrials.gov/ct2/show/NCT04732949
and look what happened.
‘….puzzling to see people blame the steroids.’
It’s not a case of blaming the steroids, but if you’re being added to another treatment, how do you separate out an effect?
Surely the steroids are the competition?
Re COPD, imho, it’s unlikely that many patients won’t be on steroids, so to exclude them means your product’s a non- starter.
Since the Sprinter protocol makes no mention of standard of care, it’s not surprising that RM appears surprised that so many trial patients are receiving steroids as a matter of course - ie as 1st line treatment.
I thought the purpose of the Trial was to see if SNG001 outperformed standard of care, not supplemented it.
There’s no mention in the Sprinter Trial protocol that I can see that patients will be receiving steroids - merely placebo.
https://clinicaltrials.gov/ct2/show/NCT04732949
Apologies for not keeping up with the debate, but my understanding of a phase 3 trial was basically ‘your drug vs the competition’ in sizeable numbers - not ‘your drug ADDED to the competition’.
So, the Sprinter trial was to test SNG001 vs standard of care(whatever that is) in the target patients not to supplement it and see which performs better.
I can’t imagine a situation, say in asthma, where a phase 3 trial would add one treatment to another. Two inhalers?!
Can someone please clarify? TIA
Apologies for post below - this looks like an update on the Original Dec 2020 study.
UK not the main focus for the company, I guess.
So, it only takes a year for the news to reach the BBC Health Unit?! Even with the ‘magical’ Oxford University tag line attached.
It’s like Polarean are doing their utmost to suppress any PR for their breakthrough technology. OK, they ****ed up their FDA application, but from all reports, users rave about those units already in place.
If the UK’s anything to go by, the Ashfield partnership gives SNG the flexibility to ‘go it alone’(I doubt) or allow any JV partner to absorb the Ashfield salesforce temporarily into their own until things get up to speed post-launch.